Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer

Phase 1TerminatedNCT02582801

Jiang Wu46 enrolled

Overview

18F-Alfatide Ⅱ PET/CT in breast cancer patients

The investigators aim to assess the clinical application of 18F-Alfatide Ⅱ PET/CT in the diagnosis and treatment response monitoring of breast cancer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

DOUBLE

Enrollment

Conditions

Breast Cancer

Interventions

18F-Alfatide Ⅱ PET/CTDRUG

Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The patients have been suspected or diagnosed with breast cancer and they have not received any treatment; It must fulfill the ethical requirements and subjects have signed an informed consent. Exclusion Criteria: * Pregnancy or nursing mothers; Those patients accompanied by other serious diseases such as cardiac functional insufficiency, hepatic and renal function insufficiency.

Locations (1)

Jinling Hospital

Nanjing, Jiangsu, China

Outcomes

Primary Outcomes

Maximum standardized uptake value (SUVmax)

the uptake intensity of lesions

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.